In Brief: FDA OHIP director
This article was originally published in The Gray Sheet
Executive Summary
FDA OHIP director: Lireka Joseph begins serving Aug. 11 as director of the Center for Devices and Radiological Health's Office of Health and Industry Programs. Joseph started her FDA career in 1979 as a medical radiation specialist in the agency's Bureau of Radiological Health and has held various posts in the center's Office of Training and Assistance (OHIP's predecessor), including assistant to the director and acting deputy director. For the past two years, Joseph has served in FDA's Office of the Commissioner as special assistant to the deputy commissioner for operations. She replaces CDRH Deputy Director for Regulations and Policy Joseph Levitt, who has been interim OHIP director since the retirement of former OHIP Director Jim Morrison. In addition, OHIP Division of Device User Programs and Systems Analysis Director Carol Vetter is slated to retire Sept. 31. Vetter's position has been filled for several months on a rotating detail basis by various CDRH staffers, which will continue until a permanent division director is named...
You may also be interested in...
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.